Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diarrhea
Patients with early Parkinsons disease experienced better symptom control and improvements in daily activities with Stalevo® than carbidopa/levodopa, according to study
December 31st, 2008
Study results published online in Movement Disorders showed that Stalevo(R) (carbidopa, levodopa and entacapone) provides better symptom control and greater improvements in activities of daily living for people with early Parkinson's disease (PD), than carbidopa/levodopa, the most widely-used current therapy. The FIRST STEP study supports regulatory filings in 2008 for the use of Stalevo in patients with early PD who have not been treated with levodopa. "The results of FIRST STEP indicate that Stalevo may be a valuable therapeutic option for patients with early Parkinson's disease," said Robert A. Hauser, MD, Professor of Neurology, Pharmacology and...
Source: Vaccine Weekly (2008-12-31)
|
